Introduction
Hereditary periodic fever syndromes are characterized by recurrent fever episodes associated with multisystemic inflammation. Several distinct diseases have been defined by molecular genetic analyses, two of which are the hyperimmunoglobulinemia D and periodic fever syndrome (HIDS; MIM no. 260920) and the tumor necrosis factor receptor-associated periodic syndrome (TRAPS; MIM no. 142680).
In HIDS patients, febrile episodes last about 3 to 7 days, recur every 4 to 8 weeks, and are accompanied, in almost all cases, by persistently high serum immunoglobulin D (IgD) levels (4100 IU/ml) and sometimes elevated IgA. 1 Other typical symptoms comprise swelling of the cervical lymph nodes, chills, headache, abdominal pain, vomiting, diarrhea, arthralgia, arthritis, skin rash, splenomegaly, and/ or hepatomegaly. 1 HIDS is an autosomal recessively inherited autoinflammatory disorder caused by mutations in the mevalonate kinase (MVK) gene on chromosome 12q24, which lead to a depressed enzymatic activity of mevalonate kinase (MK). 2, 3 More than 30 mutations have been reported in exons 2 -11 of the MVK gene. 4 The vast majority are missense mutations. Most probands are compound heterozygotes for V377I and another missense mutation, which usually results in a nonfunctional enzyme. 5 TRAPS, in contrast, is the most frequent autosomal dominantly inherited periodic fever syndrome. Attacks are associated with severe abdominal pain, localized myalgia, painful migratory erythematous skin rash, conjunctivitis, and/or periorbital edema. TRAPS is caused by mutations in exons 2 -4 and 6 of the TNFRSF1A gene on chromosome 12p13.2, which encodes the 55-kDa receptor for tumor necrosis factor. 6 Up to now, more than 40 mutations have been identified.
4,7
Patients and methods
Patient
We describe a 7-year-old German female, who initially was referred to our department with recurrent viral infections and fever up to 411C since the age of 3 months. Attacks lasted 3 to 7 days, were accompanied by increases of inflammatory parameters and interrupted by symptomfree intervals of 2 -12 weeks duration. Within the last year, these febrile episodes became shorter and were less frequent. Between fever attacks, the girl had slightly elevated serum IgD values of 129 and 127 IU/ml (normal value: o100 IU/ml), while IgA levels were within the normal range. This prompted us to determine the MK activity in peripheral blood leukocytes, which was very low with 0.02 nmol/min/mg protein (normal range: 0.4 -1.0).
Careful questioning revealed chills, vomiting, arthralgias, and cervical as well as inguinal lymphadenopathy as symptoms, which were regularly associated with the fever attacks. Occasionally, abdominal pain and diarrhea were also present. Myalgia, conjunctivitis, periorbital edema, arthritis, or rash, in contrast, were never observed. Mevalonic aciduria-specific neurologic signs were also absent.
The patient is thriving normally and shows no signs of proteinuria. Serum amyloid A levels are within the normal range.
DNA sequence analysis of the MEFV and TNFRSF1A genes EDTA blood samples were collected from the patient and all family members, and genomic DNA was isolated from white blood cells with the QIAamp blood mini kit (QIAGEN, Hilden, Germany). MVK and TNFRSF1A gene analyses were performed as described previously. 8 Analysis of leukocyte MVK activity MK activity was measured in leukocytes prepared from 3 ml of peripheral EDTA blood. 9 14 C-mevalonate-5-phosphate was separated from the substrate 14 C-mevalonic acid on a mini DEAE-cellulose column. The normal range of enzymatic activity is 0.4 -1.0 nmol/min/mg protein.
Results
DNA sequence analysis demonstrated that the girl was a compound heterozygous carrier of the most common MVK missense mutation V377I/G 1129 -A and of a novel T 1132 -C transition, leading to the replacement of serine (TCC), residue 378, by proline (CCC). This nucleotide substitution was also found in her asymptomatic father (IgD 4 IU/ml) and in her brother (IgD not detectable), but was not present on 370 control chromosomes tested, thereby strongly supporting the assumption that the S378P exchange encoded by MVK exon 11 is indeed a true mutation. Sequencing of the proband's DNA revealed, in addition, a heterozygous carrier state for the low-penetrance TNFRSF1A R92Q mutation, which was also present in her asymptomatic mother in combination with heterozygosity for the MVK V377I substitution (IgD not detectable). MK enzymatic activity in all carriers with one MVK mutation was slightly diminished, irrespective of whether residue 377 or 378 was affected (mother: 0.30 nmol/min/ mg protein; father: 0.39 nmol/min/mg protein; brother: 0.32 nmol/min/mg protein).
Discussion
In combination with heterozygosity for the common V377I mutation, the novel S378P substitution results in a distinctly diminished MK activity of 2 -5% of healthy controls. Usually, in HIDS patients without neurological symptoms, enzymatic activity is reduced to an average of 9.2% (1.8 -28.0%) with a standard deviation of 6%. 10 It is therefore quite surprising that our patient presented only with mild clinical features typical of HIDS (cervical lymphadenopathy, mild abdominal complaints, arthralgia, chills) and slightly increased IgD levels. This illustrates the wide variability in the clinical presentation of HIDS and the absence of a clear relationship between genotype, residual MK activity, and clinical features, as has been observed already by others.
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The TNFRSF1A R92Q substitution, on the other hand, is a mutation with incomplete penetrance, present in both symptomatic TRAPS patients as well as in asymptomatic controls and occurring with an allele frequency of B1% in Irish and North American control populations. 12 Heterozygosity for this low-penetrance mutation is expected to augment the intensity of the autoinflammatory response, 13, 14 thereby resulting in a more severe phenotype, especially as HIDS has been shown to be associated with increased TNF and soluble TNF receptor levels. 15 From a
Novel mevalonate kinase mutation S378P F Hoffmann et al clinical standpoint, however, this appears not to be the case in our proband. Previously, only one other patient with mutations in two autoinflammatory genes has been described. The 3-yearold boy carried two MVK mutations (G211A and V377I) and the TNFRSF1A low-penetrance P46L substitution. 16 Similar to our girl, he did not show any TRAPS-typical symptoms; however, serum TNFRSF1A levels were decreased, and he responded at least partially to TNF receptor blockade with etanercept, suggesting that the P46L mutant contributed to the phenotype. In our patient, treatment with etanercept has not yet been tried for two reasons: (1) the girl responds well to corticosteroids and (2) R92Q seems not to be associated with impaired TNF receptor shedding. 12 
